Cargando…

Interplay between Tumor Mutational Burden and Mutational Profile and Its Effect on Overall Survival: A Pilot Study of Metastatic Patients Treated with Immune Checkpoint Inhibitors

SIMPLE SUMMARY: Recently, patients with high-TMB tumors received agnostic FDA approval to be treated with pembrolizumab. However, some high-TMB patients do not show clinical benefits from this strategy. In this manuscript, we investigated a large cohort of 488 patients with TMB ≥ 10 mut/Mb treated w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xavier, Camila B., Lopes, Carlos Diego H., Awni, Beatriz M., Campos, Eduardo F., Alves, João Pedro B., Camargo, Anamaria A., Guardia, Gabriela D. A., Galante, Pedro A. F., Jardim, Denis L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Perspective
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9657500/ https://www.ncbi.nlm.nih.gov/pubmed/36358851 http://dx.doi.org/10.3390/cancers14215433

Ejemplares similares

Mutational analysis of genes coding for cell surface proteins in colorectal cancer cell lines reveal novel altered pathways, druggable mutations and mutated epitopes for targeted therapy
por: Donnard, Elisa, et al.
Publicado: (2014)

Tracing the genetic fingerprints of tumour evolution: The pursuit of identifying mutations with differential weights within the overall tumour mutation burden and their role in therapeutic responses with immune checkpoint blockade
por: Niknafs, Noushin, et al.
Publicado: (2023)

Tumor mutational burden and immune signatures interplay in renal cell carcinoma
por: Yakirevich, Evgeny, et al.
Publicado: (2020)

Comprehensive cancer-gene panels can be used to estimate mutational load and predict clinical benefit to PD-1 blockade in clinical practice
por: Campesato, Luís Felipe, et al.
Publicado: (2015)

Cytolytic activity correlates with the mutational burden and deregulated expression of immune checkpoints in colorectal cancer
por: Zaravinos, Apostolos, et al.
Publicado: (2019)

Burden of tumor mutations, neoepitopes, and other variants are weak predictors of cancer immunotherapy response and overall survival
por: Wood, Mary A., et al.
Publicado: (2020)

DNA Repair Gene Mutations as Predictors of Immune Checkpoint Inhibitor Response beyond Tumor Mutation Burden
por: Hsiehchen, David, et al.
Publicado: (2020)

Mutation burden-orthogonal tumor genomic subtypes delineate responses to immune checkpoint therapy
por: Takamatsu, Shiro, et al.
Publicado: (2022)

Pre-treatment serum albumin and mutational burden as biomarkers of response to immune checkpoint blockade
por: Yoo, Seong-Keun, et al.
Publicado: (2022)

Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors
por: Valero, Cristina, et al.
Publicado: (2021)

Interplay between Mutations and Efflux in Drug Resistant Clinical Isolates of Mycobacterium tuberculosis
por: Machado, Diana, et al.
Publicado: (2017)

High mutation burden in the checkpoint and micro-RNA processing genes in myelodysplastic syndrome
por: Moiseev, Ivan Sergeevich, et al.
Publicado: (2021)

Germline variants predictive of tumor mutational burden and immune checkpoint inhibitor efficacy
por: Chatrath, Ajay, et al.
Publicado: (2021)

Tumor mutation burden for predicting immune checkpoint blockade response: the more, the better
por: Zheng, Ming
Publicado: (2022)

The Efficacy of Tumor Mutation Burden as a Biomarker of Response to Immune Checkpoint Inhibitors
por: Moeckel, Camille, et al.
Publicado: (2023)

Clinicopathological Features, Tumor Mutational Burden, and Tumour-Infiltrating Lymphocyte Interplay in ERBB2-Mutated Breast Cancer: In Silico Analysis
por: Uchida, Shiro, et al.
Publicado: (2021)

Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy by Tumor Mutational Burden in Metastatic Castration-Resistant Prostate Cancer
por: Graf, Ryon P., et al.
Publicado: (2022)

Real-world pan-cancer landscape of frameshift mutations and their role in predicting responses to immune checkpoint inhibitors in cancers with low tumor mutational burden
por: Florou, Vaia, et al.
Publicado: (2023)

Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden
por: Morrison, Carl, et al.
Publicado: (2018)

The interplay of mutations and electronic properties in disease-related genes
por: Shih, Chi-Tin, et al.
Publicado: (2012)

Checkpoint inhibitor is active against large cell neuroendocrine carcinoma with high tumor mutation burden
por: Wang, Victoria E., et al.
Publicado: (2017)

Tumor Mutational Burden and Efficacy of Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
por: Kim, Jong Yeob, et al.
Publicado: (2019)

Tumor mutation burden predicts response and survival to immune checkpoint inhibitors: a meta-analysis
por: Wan, Linghong, et al.
Publicado: (2020)

Impact of tumor mutational burden on checkpoint inhibitor drug eligibility and outcomes across racial groups
por: Hsiehchen, David, et al.
Publicado: (2021)

Tumor mutation burden in the prognosis and response of lung cancer patients to immune-checkpoint inhibition therapies
por: Vryza, Paraskevi, et al.
Publicado: (2023)

Suspected Germline TP53 Variants and Clonal Hematopoiesis of Indeterminate Potential: Lessons Learned From a Molecular Tumor Board
por: Xavier, Camila B, et al.
Publicado: (2023)

Cardiovascular toxicity following immune checkpoint inhibitors: A systematic review and meta-analysis
por: Xavier, Camila Bragança, et al.
Publicado: (2022)

Alternative Polyadenylation Allows Differential Negative Feedback of Human miRNA miR-579 on Its Host Gene ZFR
por: Hinske, Ludwig Christian, et al.
Publicado: (2015)

Contributions of the Intrinsic Mutation Process to Cancer Mutation and Risk Burdens
por: Zhu, Wei, et al.
Publicado: (2017)

Tumor Mutational Burden in Real-World Patients With Pancreatic Cancer: Genomic Alterations and Predictive Value for Immune Checkpoint Inhibitor Effectiveness
por: Quintanilha, Julia C.F., et al.
Publicado: (2023)

Discordance in Tumor Mutation Burden from Blood and Tissue Affects Association with Response to Immune Checkpoint Inhibition in Real-World Settings
por: Sturgill, Emma G, et al.
Publicado: (2022)

The interplay between cancer type, panel size and tumor mutational burden threshold in patient selection for cancer immunotherapy
por: Golkaram, Mahdi, et al.
Publicado: (2020)

KRAS mutations and endometriosis burden of disease
por: Orr, Natasha L, et al.
Publicado: (2023)

Discussion of tumor mutation burden as an indicator to predict efficacy of immune checkpoint inhibitors: A case report
por: Wu, Mingrui, et al.
Publicado: (2022)

Lynch syndrome-associated chordoma with high tumor mutational burden and significant response to immune checkpoint inhibitors
por: Shinojima, Naoki, et al.
Publicado: (2023)

Tumor mutational burden predicts survival in patients with low-grade gliomas expressing mutated IDH1
por: Alghamri, Mahmoud S, et al.
Publicado: (2020)

Gene Copy-Number Polymorphism Caused by Retrotransposition in Humans
por: Schrider, Daniel R., et al.
Publicado: (2013)

Recurrent somatic mutation in DROSHA induces microRNA profile changes in Wilms tumour
por: Torrezan, Giovana T., et al.
Publicado: (2014)

High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint inhibitors
por: Maleki Vareki, Saman
Publicado: (2018)

Dose-Dependent Effect of Tumor Mutation Burden on Cancer Prognosis Following Immune Checkpoint Blockade: Causal Implications
por: Zheng, Ming
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_c0tda9fl75j2tscfveo1m51vvs